Supported by an educational grant from Neurocrine Biosciences, Inc.

News

Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds

Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, vesicular monoamine transporter type 2 (VMAT2), in functi

All News

Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds

A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of

Patient Survey Identifies Barriers to TD Treatment

Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according

FDA Approves First Schizophrenia Treatment in Over 3 Decades

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of

TD Has ‘Severe Impact’ on Patients and Caregivers

Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both p

FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD

At the end of April, Neurocrine Biosciences, Inc.